From the Division of Female Pelvic Medicine and Reconstructive Surgery, Department of Obstetrics and Gynecology.
Division of Clinical Research, Department of Obstetrics and Gynecology.
Female Pelvic Med Reconstr Surg. 2022 Mar 1;28(3):e62-e65. doi: 10.1097/SPV.0000000000001144.
d-Mannose is a promising nonantibiotic prophylaxis for recurrent urinary tract infection (rUTI). Recurrent UTI is common in postmenopausal women and may be especially prevalent in those with cystitis cystica (CC) lesions found on cystoscopy. Our objectives were to determine whether CC lesions are associated with a higher UTI incidence rate and whether d-mannose reduces this rate in women with CC.
This is a retrospective cohort study of patients with rUTI who underwent cystoscopy at our institution (from which CC status was identified) and who were treated with d-mannose as a single agent for UTI prophylaxis. Participants were required to have at least 1 year of follow-up for UTIs both before and after d-mannose initiation to allow for a pre-post comparison.
Twenty-seven patients were included in the analysis (13 with CC, 14 without CC). Most patients (88.9%) were postmenopausal. Patients with CC had a higher UTI incidence rate than patients without CC (4.69 vs 2.93 UTIs/year before starting d-mannose prophylaxis, P = 0.021). After initiating d-mannose prophylaxis, the UTI incidence rate decreased significantly in patients with CC (rate decrease = 2.23 UTIs/year, P = 0.0028). This decrease was similar in magnitude to that observed in patients without CC (rate decrease = 1.64 UTIs/year, P = 0.0007; P interaction = 0.58).
Patients with rUTI with CC had more frequent UTI episodes than patients without CC. Patients in both groups had fewer UTI episodes after beginning d-mannose prophylaxis. These findings add to the body of literature supporting d-mannose for the prevention of rUTI in women, including those with CC.
D-甘露糖是一种很有前途的非抗生素复发性尿路感染(rUTI)预防药物。绝经后妇女常见复发性尿路感染,且在膀胱镜检查发现膀胱囊性膀胱炎(CC)病变的患者中可能更为普遍。我们的目的是确定 CC 病变是否与更高的尿路感染发生率相关,以及 D-甘露糖是否能降低 CC 患者的尿路感染发生率。
这是一项回顾性队列研究,纳入在我院接受膀胱镜检查(从中确定 CC 状态)并接受 D-甘露糖作为单一药物进行尿路感染预防治疗的 rUTI 患者。参与者需要在开始 D-甘露糖预防之前和之后至少有 1 年的尿路感染随访记录,以便进行前后比较。
共纳入 27 例患者(13 例有 CC,14 例无 CC)进行分析。大多数患者(88.9%)为绝经后女性。与无 CC 的患者相比,CC 患者的尿路感染发生率更高(开始 D-甘露糖预防前分别为 4.69 和 2.93 次/年,P=0.021)。开始 D-甘露糖预防后,CC 患者的尿路感染发生率显著降低(发生率降低=2.23 次/年,P=0.0028)。这一降幅与无 CC 的患者相似(发生率降低=1.64 次/年,P=0.0007;P 交互=0.58)。
有 CC 的 rUTI 患者比无 CC 的患者发生尿路感染的次数更频繁。两组患者在开始 D-甘露糖预防后发生尿路感染的次数均减少。这些发现为支持 D-甘露糖预防女性 rUTI,包括 CC 患者,提供了更多的文献依据。